Study showed MiniMed™ 780G system achieved ADA-recommended time-in-range goals even on days users forgot to bolus

Rhea-AI Summary

Medtronic (MDT) announced a real-world retrospective analysis (CareLink data, Jan 2, 2020–Mar 31, 2025) showing MiniMed 780G users achieved ADA-recommended time-in-range (TIR) goals even on days when mealtime boluses were missed.

Key results: 76.3% TIR on missed-bolus days with recommended optimal settings (100 mg/dL target; 2-hour active insulin time) vs 69.3% TIR for other settings; mean sensor glucose 149 mg/dL vs 160 mg/dL; GMI 6.9% vs 7.1%; >61% met all three ADA targets vs 36.6%.

Study used N=369,467 users (No Bolus cohort N=54,553); deliberate no-bolus is off-label and not recommended.

Positive

• TIR 76.3% on missed-bolus days with recommended settings
• Mean sensor glucose 149 mg/dL with recommended settings
• >61% met all three ADA targets on missed-bolus days

Negative

• Deliberate no-bolus is off-label and not approved for MiniMed 780G
• Non-recommended settings produced lower TIR (69.3%)
• Retrospective CareLink analysis may reflect selection and consent biases

Key Figures

Time-in-range (TIR) 76.3% Missed bolus days with recommended optimal settings on MiniMed 780G

Users meeting ADA TIR goal 71.2% MiniMed 780G users achieving ADA-recommended TIR on missed bolus days

Study population N=369,467 Global CareLink MiniMed 780G users analyzed

No-bolus users N=54,553 Users with ≥10 days without bolusing included in analysis

Optimal settings subgroup N=12,723 No-bolus days with recommended optimal settings

Non-optimal settings subgroup N=41,830 No-bolus days without recommended optimal settings

Mean sensor glucose 149 mg/dL Missed bolus days with recommended optimal settings

Glucose Management Indicator 6.9% Missed bolus days with recommended optimal settings

Market Reality Check

$97.53 Last Close

Volume Volume 6,622,021 is 10% above the 20-day average of 6,007,132, showing moderately elevated trading activity. normal

Technical Price at $100.31 is trading above the 200-day MA $91.38 and about 5.66% below the 52-week high of $106.33.

Peers on Argus

Medtronic gained 3.03% with supportive MiniMed 780G data, while key medical device peers like SYK +4.42%, ZBH +3.16%, BSX +2.02%, PHG +2.06%, and EW +1.73% also traded higher, suggesting broader sector strength even though the momentum scanner did not flag a coordinated sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 19	Diabetes IPO plan	Neutral	-0.9%	Filed Form S-1 for planned IPO and future split-off of Diabetes unit.
Dec 04	Dividend declaration	Positive	-0.6%	Announced $0.71 Q3 FY26 dividend, extending 48-year dividend growth streak.
Dec 03	FDA device clearance	Positive	+0.0%	Received FDA clearance for Hugo™ RAS system for key urologic procedures.
Dec 02	780G US launch	Positive	-1.3%	Started U.S. commercial launch of MiniMed™ 780G with Abbott Instinct sensor.
Nov 18	Earnings results	Positive	+4.7%	Reported Q2 FY26 revenue and EPS growth, raised full-year guidance.

Pattern Detected

Recent history shows strong alignment between positive earnings news and upside moves, but mixed to negative reactions around device launches and other corporate announcements.

Recent Company History

Over the last months, Medtronic reported strong Q2 FY26 results on Nov 18, 2025 with $8.96B revenue and raised guidance, which was followed by a notable positive price reaction. Subsequent device and diabetes updates, including the U.S. MiniMed™ 780G launch on Dec 2, 2025 and FDA clearance of the Hugo™ RAS system, saw muted to negative moves. Dividend and IPO-related announcements in December were accompanied by slight declines. Today’s MiniMed™ 780G real-world data fits the ongoing focus on the Diabetes segment and that business’s planned separation.

Market Pulse Summary

This announcement highlights real-world MiniMed™ 780G performance, with users achieving 76.3% time-in-range and 71.2% meeting ADA goals on missed bolus days when using recommended settings. It builds on recent MiniMed 780G launch momentum and Medtronic’s growing Diabetes revenue base. Investors may track further real-world datasets, usage patterns in both type 1 and type 2 diabetes, and how these outcomes support the planned MiniMed IPO alongside overall fiscal 2026 growth and guidance.

Key Terms

time-in-range medical

"achieved American Diabetes Association (ADA) recommended goals for time-in-range (TIR)"

Time-in-range measures the percentage of time a person’s blood sugar stays within a pre-set target window, typically tracked continuously by glucose monitors. For investors, it’s a practical outcome metric: higher time-in-range signals a drug, device or care program is keeping patients healthier (like a thermostat maintaining a comfortable temperature), which can drive user adoption, clinical credibility, insurance support and commercial value.

bolus medical

"even on days when mealtime boluses were missed"

A bolus is a single, concentrated dose of a drug or fluid given all at once rather than slowly over time, like taking a quick gulp instead of sipping. Investors should care because a bolus can change how fast a medicine works, its side effect risks, and how regulators view dosing safety; those factors can materially affect clinical trial outcomes, approval chances and commercial prospects.

automated insulin delivery medical

"all automated insulin delivery systems, including the MiniMed™ 780G system"

A system that links a glucose sensor, an insulin pump, and control software so insulin is adjusted automatically to keep blood sugar near a target range, similar to a smart thermostat that regulates room temperature. It matters to investors because it replaces manual dosing with continuous, data-driven care, which can drive device sales, recurring subscription software services, better health outcomes, and regulatory interest—factors that affect market growth and company valuation.

glucose management indicator medical

"Glucose Management Indicator: 6.9% vs. 7.1%"

Glucose Management Indicator (GMI) is a number calculated from continuous glucose monitor (CGM) readings that translates average blood sugar patterns into an estimate comparable to a lab A1c result. Think of it as converting a stream of daily temperature readings into a single seasonal average; it helps clinicians and patients see overall control from device data. Investors care because GMI is often used to show how well diabetes drugs or devices work, influence regulatory decisions, and affect market adoption and reimbursement.

advanced hybrid closed loop medical

"after advanced hybrid closed loop (AHCL) initiation were included in analyses"

An advanced hybrid closed loop is a medical device system that combines a continuous glucose monitor and an insulin pump with smart software that automatically adjusts most insulin delivery to keep blood sugar in range, while still asking the user to enter carbohydrates for meals. Think of it like cruise control for blood sugar that handles routine adjustments but relies on the driver for big changes; for investors, adoption, regulatory approval, and payer coverage determine how much this product class can drive recurring sales and competitive advantage.

insulin pump medical

"using the MiniMed™ 780G insulin pump with a compatible Medtronic sensor"

A small wearable medical device that delivers measured doses of insulin automatically or on demand to help people with diabetes regulate their blood sugar, often replacing multiple daily injections. Investors care because these devices combine hardware, software and supplies to create recurring revenue, are subject to regulatory approval and reimbursement decisions, and can change competitive dynamics in a large, growing healthcare market much like a smartphone platform reshapes accessory sales.

AI-generated analysis. Not financial advice.

GALWAY, Ireland, Jan. 7, 2026 /PRNewswire/ -- A new real-world retrospective analysis published in Diabetes Care showed that users of the MiniMed™ 780G system achieved American Diabetes Association (ADA) recommended goals for time-in-range (TIR)— even on days when mealtime boluses were missed. CareLink™ data showed that the studied user population achieved 76.3% TIR on missed bolus days when using SmartGuard™ technology with recommended optimal settings (100 mg/dL glucose target; two-hour active insulin time). The study investigated off-label user behavior as the system labeling requires users to announce meals when using SmartGuard™ technology. Deliberately not bolusing is an unapproved use of the device and is not recommended. While meal announcement is required, this study highlights the importance of optimized settings, especially when some users occasionally missed boluses.

Mealtime burden
Mealtimes are one of the biggest challenges for people living with type 1 diabetes and frequently linked to diabetes distress.^1,2 The constant need for decision-making and mental load around calculating carbohydrates and insulin requirements at mealtimes contributes to the overall burden of the condition. Missed boluses can significantly impact diabetes management and glycemic outcomes. A 2024 study published in Diabetes Technology & Therapeutics found that children and adolescents using AID systems missed an average of 2.2 boluses per day, with each additional missed bolus reducing TIR by nearly 10%.³

"While labeling requires meal bolusing for all automated insulin delivery systems, including the MiniMed™ 780G system, missed boluses are a reality in real-world use," said Jennifer McVean, MD, Senior Medical Affairs Director, Medtronic Diabetes, and lead investigator of the study. "Using real-world CareLink™ data, this analysis showed that when using recommended optimal settings, 71.2% of MiniMed™ 780G system users studies achieved ADA-recommended TIR goals on days when meal boluses were missed."

While announcing meals is required per the labeling of the MiniMed™ 780G system, the algorithm adjusts the delivery of insulin every five minutes based on sensor readings to auto-correct^† glucose levels—providing support when boluses are occasionally missed or carbohydrates are underestimated. The MiniMed™ 780G system is not approved for no bolusing for meals. 

Study Design & Key Findings
The study retrospectively analyzed real-world global CareLink user data (N=369,467) of those using the MiniMed™ 780G insulin pump with a compatible Medtronic sensor^‡ who experienced at least 10 days without bolusing (N=54,553) between January 2, 2020 to March 31, 2025.  

The analysis compared glycemic outcomes on missed bolus days with (N=12,723) and without (N=41,830) use of the recommended optimal settings. Those using the recommended optimal settings achieved significantly better outcomes than those using other settings in all age groups, including both type 1diabetes and type 2 diabetes populations:

• TIR: 76.3% recommended optimal settings vs. 69.3% for non-recommended optimal users
• Mean Sensor Glucose: 149 mg/dL vs. 160 mg/dL
• Glucose Management Indicator: 6.9% vs. 7.1%
• More than 61% of recommended optimal setting users met all three of the ADA recommended glycemic targets on missed bolus days compared to 36.6% in users of other settings

"These findings underscore the advanced capabilities of the MiniMed™ 780G system and its potential to ease the daily burden of diabetes care," said Que Dallara, EVP and President of Medtronic Diabetes. "Our goal is to empower people with technology that adapts to their lives, even when things don't go as planned."

†	Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.
§	Refers to SmartGuard™ feature. Individual results may vary.
‡	"CareLink Personal" data from January 2020 to March 31, 2025 were extracted from global MiniMed™ 780G system users who provided consent. Users with ≥10 days of sensor glucose data before automation and users with ≥10 days of sensor glucose data after advanced hybrid closed loop (AHCL) initiation were included in analyses. A "No Bolus" population was defined as users who did not administer boluses for ≥10 days; and only those days without user-initiated boluses were analyzed. These days were not required to be consecutive. The datasets included individuals who self-reported age (i.e. ≤15, 16-28, 29-42, 43-55, ≥56 years) and diagnosis of type 1 diabetes (T1D) or type 2 diabetes (T2D).
1	Bergenstal RM, et al. Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes. Diabetes Care. 2021; Published online.
2	Monaghan M, Herbert LJ, Wang J, Holmes C, Cogen FR, Streisand R. Mealtime behavior and diabetes-specific parent functioning in young children with type 1 diabetes. Health Psychol. 2015 Aug;34(8):794-801. doi: 10.1037/hea0000204. Epub 2015 Feb 9. P
3	Laugesen C, et al. Impact of Missed and Late Meal Boluses on Glycemic Outcomes in Automated Insulin Delivery-Treated Children and Adolescents with Type 1 Diabetes. *Diabetes Technol Ther*. 2024;26(12):897-907.

About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to make diabetes more predictable, so everyone can embrace life to the fullest with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Janet Cho
Global Communications
+1 (818) 403-7028

Ryan Weispfenning
Investor Relations
+1 (763) 505-4626

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/study-showed-minimed-780g-system-achieved-ada-recommended-time-in-range-goals-even-on-days-users-forgot-to-bolus-302655231.html

SOURCE Medtronic plc

FAQ

What did the January 7, 2026 MiniMed 780G study say about missed boluses (MDT)?

The study found users with recommended optimal settings achieved 76.3% TIR on missed-bolus days versus 69.3% TIR for other settings.

How many users and what timeframe did the MiniMed 780G CareLink analysis cover for MDT?

The retrospective analysis used global CareLink data from Jan 2, 2020 to Mar 31, 2025 with N=369,467 total users and a No Bolus cohort of N=54,553.

Does the MiniMed 780G support skipping meal boluses according to the January 2026 release?

No. The company said deliberate no-bolus use is off-label and not recommended; labeling requires meal announcement and bolusing.

What clinical metrics improved with recommended optimal settings in the MDT MiniMed 780G study?

Recommended settings produced TIR 76.3%, mean sensor glucose 149 mg/dL, and GMI 6.9% on missed-bolus days.

How many users met ADA glycemic targets on missed-bolus days in the MDT study?

More than 61% of recommended-setting users met all three ADA targets versus 36.6% for other settings.

What is the practical investor implication of the MiniMed 780G study for MDT shareholders?

The analysis suggests the device may maintain strong glycemic control on missed-bolus days when recommended settings are used, reinforcing product value; deliberate no-bolus use remains off-label.